DOCSLIB.ORG

Norethisterone and Its Acetate – What's So Special About Them?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Norethisterone and Its Acetate – What's So Special About Them? BMJ Sex Reprod Health: first published as 10.1136/bmjsrh-2020-200619 on 12 May 2020. Downloaded from Review Norethisterone and its acetate – what’s so special about them? Emilia Huvinen , Elina Holopainen , Oskari Heikinheimo Obstetrics and Gynecology, ABSTRACT Key message points University of Helsinki and Introduction Progestogens (progestins) Helsinki University Hospital, are widely used for contraception, in Helsinki 00029, Finland ► Norethisterone (NET) converts in part postmenopausal hormone therapy, and in to ethinylestradiol (EE); 10–20 mg NET Correspondence to treatment of abnormal uterine bleeding and equals 20–30 µg EE. Dr Emilia Huvinen, Obstetrics endometriosis. Norethisterone (NET) and its and Gynecology, University of ► NET has a strong influence on the acetate (NETA) differ from other progestogens by Helsinki and Helsinki University endometrium and it is a good option for Hospital, Helsinki 00029, Finland; their partial conversion to ethinylestradiol (EE). treatment of endometrial hyperplasia. emilia. huvinen@ helsinki. fi We review their special characteristics and focus ► Special consideration is needed in cases on the clinically relevant risk factors associated Received 17 February 2020 of high risk for thromboembolic events Revised 6 April 2020 with estrogen action, such as migraine with aura and when treating women experiencing Accepted 13 April 2020 and risk of thrombosis. migraine with aura. Published Online First Methods Narrative review based on a medical 12 May 2020 literature (OvidMedline and PubMed) search. Results NET converts to significant amounts of EE; 10–20 mg NET corresponds to 20–30 µg used for contraception, postponing EE. The effects of NET on the endometrium are menstruation, as part of postmenopausal pronounced, making it a good choice for treating hormonal therapy (HT), and for the treat- abnormal uterine bleeding, endometriosis, and ment of abnormal uterine bleeding and endometrial hyperplasia. NET also has beneficial endometriosis. Although all progestogens effects on bone mineral density and positive imitate natural progesterone, each proges- or neutral effects on cardiovascular health. togen also has its individual characteristics Conversely, long- term use of NET is associated based on the different pharmacokinetic with a slightly increased breast cancer risk, and pharmacodynamic characteristics, http://jfprhc.bmj.com/ and the risk of venous thromboembolism is namely different binding affinities to moderately increased. This risk seems to be dose- estrogen, androgen, and glucocorticoid dependent; contraceptive use carries no risk, and mineralocorticoid receptors.1 The but therapeutic doses might be associated with availability and use of different progesto- an increased risk. Studies suggest an association gens vary globally. between combinations of EE and progestogens Norethisterone (NET) (and simi- and ischaemic stroke, which in particular larly norethisterone acetate, NETA, and on September 28, 2021 by guest. Protected copyright. concerns women with migraine. No studies norethindrone) is the most widely used have, however, assessed this risk related to the progestogen in several European coun- therapeutic use of NET. tries. It is an effective progestogen with a Conclusions NET is a potent progestogen, strong endometrial effect.2 In contrast to especially when considering the endometrium. other progestogens, NET partly converts Its partial conversion to EE, however, is important (approximately 0.4%–1%) to ethinyl- to remember. Clinical consideration is required estradiol (EE) in the liver, therefore also with women at high risk for either breast cancer 3 4 causing estrogenic effects in the body. or thromboembolism, or experiencing migraine © Author(s) (or their As preceding estrogen action is needed for employer(s)) 2021. No with aura. progestogen activity, the resulting EE also commercial re- use. See rights strengthens the progestogenic proper- and permissions. Published by BMJ. ties of NET. However, considering the 5 thromboembolic risk associated with EE, To cite: Huvinen E, Holopainen E, Heikinheimo O. INTRODUCTION this conversion might be of importance BMJ Sex Reprod Health Progestogens (progestins) are synthetic concerning the possible adverse effects of 2021;47:102–109. analogues of progesterone, and are widely NET(A). 102 Huvinen E, et al. BMJ Sex Reprod Health 2021;47:102–109. doi:10.1136/bmjsrh-2020-200619 none) generationsthehighest. fourth (eg,drospire gestodene anddesogestrel) and thromboembolic complications, andthethird (eg, gens (eg,levonorgestrel) for contraception.Thesecond- estrogen different progestogensincombination with of when discussing thethromboticeffects especially generations accordingtotheirorderofdiscovery, tone)( from spironolac (eg, drospirenone derived and others 17- into 19- ically classified accordingtotheprecursor molecules gens (eg, desogestrel) are prodrugs, and are effective prodrugs, and are are gens (eg,desogestrel) natural progesterone isless complete.Some progesto the gastrointestinaltractis effective,whereasthatof of 19- the absorption example, For characteristics. cokinetic theydifferintheirpharma receptors. Additionally, mineralocorticoid progesterone, glucocorticoid,and steroid receptors,namelyestrogen,androgen, cellular profile basedontheirdistinctiveabilityto bind structure. of discoveryorchemical and steroidresearch. of contraception This keyinvention changedthefield increased absorptionfrom the gastrointestinalcanal. tion ofanethylgrouptoC17resultedinsignificantly theaddi molecule toaprogestogenic one. Moreover, from C19oftestosterone, converting an androgenic The approachinvolvedtheremovalofamethyl group created byCarlDrejassifrom natural testosterone. the firstsyntheticprogestogen, norethisterone, was andfinallyin1951, progesterone had poor efficiency; orally administered of ovulationinhibition.Natural, In theearly1900s,scientistsstrivedtofindameans PROGESTOGENS with NET*. conjunction and psychologic*in metabolism, bone, endometr*, glucose embol*, thrombo*,breast cancer, searchtermswerethrombo in English.Additional only articles and included estradiol/EE with ethinyl and norethindron*, individuallyand incombination norethisterone, norethisteron*, terms progest*,NETA, usedthesearch and reviewsonnorethisterone. We usedOvidMedlineandPubMedtofindstudies We METHODS cations fortheuseofEE. migraine withaura,typicallyconsideredascontraindi women athigherriskforthromboemboliceventsand cially wanted tofocusoncertainriskgroups such as espe use. We to considertheirimplicationsforclinical and of NET, effects potentially negative and beneficial Progestogens can alsobegroupedintodifferent Progestogens All progestogens have a slightly different clinical All progestogens havea to theirtime according classified canbe Progestogens The purposeofthisreviewistoassessthespecific α hydroxyprogesterone derivatives(pregnanes), hydroxyprogesterone table nortestosterone nortest 1 ). osterone (estranes andgonanes) and 6 derivatives (suchasNET)from display thelowestriskof 7–10 generation progesto 1 Theyarechem - - - - - - - - - - Table 1 Pharmacology and biological activity of progesterone and synthetic progestogens (adapted from Schindler et al)1 Progestogen Progestogenic Antigonadotropic Anti- estrogenic Estrogenic Androgenic Anti- androgenic Glucocorticoid Antimineralocorticoid Progesterone + + + – – +/– + + Medroxyprogesterone acetate (MPA) + + + – +/– – + – Dydrogesterone + – + – – +/– – +/– First generation Norethisterone (NET) + + + + + – – – Lynestrenol* + + + + + – – – Cyproterone acetate + + + – – ++ + – Second generation Levonorgestrel + + + – + – – – Third generation Desogestrel + + + – + – – – Norgestimate† + + + – + – – – Gestodene + + + – + – + + Fourth generation Drospirenone + + + – – + – + Nomegestrol acetate + + + – – +/– – – Review Dienogest + + +/– +/– – + – – 103 *Prodrug. †Approximately 22% converts to levonorgestrel.11 Huvinen E, et al. BMJ Sex Reprod Health 2021;47:102–109. doi:10.1136/bmjsrh-2020-200619 BMJ Sex Reprod Health: first published as 10.1136/bmjsrh-2020-200619 on 12 May 2020. Downloaded from from Downloaded 2020. May 12 on 10.1136/bmjsrh-2020-200619 as published first Health: Reprod Sex BMJ http://jfprhc.bmj.com/ on September 28, 2021 by guest. Protected by copyright. by Protected guest. by 2021 28, September on BMJ Sex Reprod Health: first published as 10.1136/bmjsrh-2020-200619 on 12 May 2020. Downloaded from Review only following conversion by first- pass metabolism the androgenic activity of NET might partly compen- to an effective compound (3α-ketodesogestrel, that sate the effects of EE in the liver. is, etonogestrel). Progestogens bind to serum proteins Later in 2007, Chu et al conducted a study on 20 such as sex hormone-binding globulin (SHBG), premenopausal women, randomised to receive either corticosteroid- binding globulin (CBG), and albumin. 10, 20, or 40 mg NETA for 7 days in the follicular In addition, individual differences in metabolism can phase of the menstrual cycle.4 The conversion rate multiply the differences in their serum concentrations of NETA to EE was estimated to be at least 0.14 %, up to five- fold.11 but even up to 0.20%–0.33%. For comparison, inges- Therefore, the equivalent progestogen doses needed tion of 30–40 µg EE leads to a plasma concentration for ovulation inhibition and endometrial transforma- of 100–135 pg/mL, whereas the EE concentration tion vary. The doses required, especially for endo- following 10 mg NETA was 58 pg/mL, and following metrial transformation, are also
Load more

Recommended publications
  • Index Vol. 12-15
    353 INDEX VOL. 12-15 Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgefiihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. The references of the Subject Index are given in the language of the respective contribution. 14 AAG (Alpha-acid glycoprotein) 120 14 Adenosine 108 12 Abortion 151 12 Adenosine-phosphate 311 13 Abscisin 12, 46, 66 13 Adenosine-5'-phosphosulfate 148 14 Absorbierbarkeit 317 13 Adenosine triphosphate 358 14 Absorption 309, 350 15 S-Adenosylmethionine 261 13 Absorption of drugs 139 13 Adipaenin (Spasmolytin) 318 14 - 15 12 Adrenal atrophy 96 14 Absorptionsgeschwindigkeit 300, 306 14 - 163, 164 14 Absorptionsquote 324 13 Adrenal gland 362 14 ACAI (Anticorticocatabolic activity in­ 12 Adrenalin(e) 319 dex) 145 14 - 209, 210 12 Acalo 197 15 - 161 13 Aceclidine (3-Acetoxyquinuclidine) 307, 13 {i-Adrenergic blockers 119 308, 310, 311, 330, 332 13 Adrenergic-blocking activity 56 13 Acedapsone 193,195,197 14 O(-Adrenergic blocking drugs 36, 37, 43 13 Aceperone (Acetabutone) 121 14 {i-Adrenergic blocking drugs 38 12 Acepromazin (Plegizil) 200 14 Adrenergic drugs 90 15 Acetanilid 156 12 Adrenocorticosteroids 14, 30 15 Acetazolamide 219 12 Adrenocorticotropic hormone (ACTH) 13 Acetoacetyl-coenzyme A 258 16,30,155 12 Acetohexamide 16 14 - 149,153,163,165,167,171 15 1-Acetoxy-8-aminooctahydroindolizin 15 Adrenocorticotropin (ACTH) 216 (Slaframin) 168 14 Adrenosterone 153 13 4-Acetoxy-1-azabicyclo(3, 2, 2)-nonane 12 Adreson 252
    [Show full text]
  • Detectx® Serum 17Β-Estradiol Enzyme Immunoassay Kit
    DetectX® Serum 17β-Estradiol Enzyme Immunoassay Kit 1 Plate Kit Catalog Number KB30-H1 5 Plate Kit Catalog Number KB30-H5 Species Independent Sample Types Validated: Multi-Species Serum and Plasma Please read this insert completely prior to using the product. For research use only. Not for use in diagnostic procedures. www.ArborAssays.com KB30-H WEB 210308 TABLE OF CONTENTS Background 3 Assay Principle 4 Related Products 4 Supplied Components 5 Storage Instructions 5 Other Materials Required 6 Precautions 6 Sample Types 7 Sample Preparation 7 Reagent Preparation 8 Assay Protocol 9 Calculation of Results 10 Typical Data 10-11 Validation Data Sensitivity, Linearity, etc. 11-13 Samples Values and Cross Reactivity 14 Warranty & Contact Information 15 Plate Layout Sheet 16 ® 2 EXPECT ASSAY ARTISTRY KB30-H WEB 210308 BACKGROUND 17β-Estradiol, C18H24O2, also known as E2 or oestradiol (1, 3, 5(10)-Estratrien-3, 17β-diol) is a key regulator of growth, differentiation, and function in a wide array of tissues, including the male and female reproductive tracts, mammary gland, brain, skeletal and cardiovascular systems. The predominant biological effects of E2 are mediated through two distinct intracellular receptors, ERα and ERβ, each encoded by unique genes possessing the functional domain characteristics of the steroid/thyroid hormone superfamily of nuclear receptors1. ERα is the predominant form expressed in the breast, uterus, cervix, and vagina. ERβ exhibits a more limited pattern and is primarily expressed in the ovary, prostate, testis, spleen, lung, hypothalamus, and thymus2. Estradiol also influences bone growth, brain development and maturation, and food intake3, and it is also critical in maintaining organ functions during severe trauma4,5.
    [Show full text]
  • A Guide to Feminizing Hormones – Estrogen
    1 | Feminizing Hormones ​ ​ A Guide to Feminizing Hormones Hormone therapy is an option that can help transgender and gender-diverse people feel more comfortable in their bodies. Like other medical treatments, there are benefits and risks. Knowing what to expect will help us work together to maximize the benefits and minimize the risks. What are hormones? Hormones are chemical messengers that tell the body’s cells how to function, ​ when to grow, when to divide, and when to die. They regulate many functions, including growth, sex drive, hunger, thirst, digestion, metabolism, fat burning & storage, blood sugar, cholesterol levels, and reproduction. What are sex hormones? Sex hormones regulate the development of sex characteristics, including the sex ​ organs such as genitals and ovaries/testicles. Sex hormones also affect the secondary sex characteristics that typically develop at puberty, like facial and body hair, bone growth, breast growth, and voice changes. There are three categories of sex hormones in the body: • Androgens: testosterone, dehydroepiandrosterone (DHEA), ​ dihydrotestosterone (DHT) • Estrogens: estradiol, estriol, estrone ​ • Progestin: progesterone ​ Generally, “males” tend to have higher androgen levels, and “females” tend to have higher levels of estrogens and progestogens. What is hormone therapy? Hormone therapy is taking medicine to change the levels of sex hormones in your body. Changing these levels will affect your hair growth, voice pitch, fat distribution, muscle mass, and other features associated with sex and gender. Feminizing hormone therapy can help make the body look and feel less “masculine” and more “feminine" — making your body more closely match your identity. What medicines are involved? There are different kinds of medicines used to change the levels of sex hormones in your body.
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • Gender-Affirming Hormone Therapy
    GENDER-AFFIRMING HORMONE THERAPY Julie Thompson, PA-C Medical Director of Trans Health, Fenway Health March 2020 fenwayhealth.org GOALS AND OBJECTIVES 1. Review process of initiating hormone therapy through the informed consent model 2. Provide an overview of masculinizing and feminizing hormone therapy 3. Review realistic expectations and benefits of hormone therapy vs their associated risks 4. Discuss recommendations for monitoring fenwayhealth.org PROTOCOLS AND STANDARDS OF CARE fenwayhealth.org WPATH STANDARDS OF CARE, 2011 The criteria for hormone therapy are as follows: 1. Well-documented, persistent (at least 6mo) gender dysphoria 2. Capacity to make a fully informed decision and to consent for treatment 3. Age of majority in a given country 4. If significant medical or mental health concerns are present, they must be reasonably well controlled fenwayhealth.org INFORMED CONSENT MODEL ▪ Requires healthcare provider to ▪ Effectively communicate benefits, risks and alternatives of treatment to patient ▪ Assess that the patient is able to understand and consent to the treatment ▪ Informed consent model does not preclude mental health care! ▪ Recognizes that prescribing decision ultimately rests with clinical judgment of provider working together with the patient ▪ Recognizes patient autonomy and empowers self-agency ▪ Decreases barriers to medically necessary care fenwayhealth.org INITIAL VISITS ▪ Review history of gender experience and patient’s goals ▪ Document prior hormone use ▪ Assess appropriateness for gender affirming medical
    [Show full text]
  • Minutes of PRAC Meeting on 09-12 July 2018
    6 September 2018 EMA/PRAC/576790/2018 Inspections, Human Medicines Pharmacovigilance and Committees Division Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of the meeting on 09-12 July 2018 Chair: June Raine – Vice-Chair: Almath Spooner Health and safety information In accordance with the Agency’s health and safety policy, delegates were briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scope listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised. Of note, the minutes are a working document primarily designed for PRAC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1). 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018.
    [Show full text]
  • Quantitative High-Throughput Profiling of Environmental Chemicals and Drugs That Modulate Farnesoid X Receptor
    OPEN Quantitative High-Throughput Profiling of SUBJECT AREAS: Environmental Chemicals and Drugs that SCREENING SMALL MOLECULES Modulate Farnesoid X Receptor Chia-Wen Hsu1, Jinghua Zhao1, Ruili Huang1, Jui-Hua Hsieh2, Jon Hamm3, Xiaoqing Chang3, Keith Houck4 Received & Menghang Xia1 27 June 2014 Accepted 1National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, 2Division of the National 29 August 2014 Toxicology Program, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, 3Integrated Laboratory Systems, Inc., Morrisville, NC, 4U.S. Environmental Protection Agency, Research Triangle Park, NC. Published 26 September 2014 The farnesoid X receptor (FXR) regulates the homeostasis of bile acids, lipids, and glucose. Because endogenous chemicals bind and activate FXR, it is important to examine which xenobiotic compounds Correspondence and would disrupt normal receptor function. We used a cell-based human FXR b-lactamase (Bla) reporter gene assay to profile the Tox21 10K compound collection of environmental chemicals and drugs. requests for materials Structure-activity relationships of FXR-active compounds revealed by this screening were then compared should be addressed to against the androgen receptor, estrogen receptor a, peroxisome proliferator-activated receptors d and c, and M.X. ([email protected]. the vitamin D receptor. We identified several FXR-active structural classes including anthracyclines, gov) benzimidazoles, dihydropyridines, pyrethroids, retinoic acids, and vinca alkaloids. Microtubule inhibitors potently decreased FXR reporter gene activity. Pyrethroids specifically antagonized FXR transactivation. Anthracyclines affected reporter activity in all tested assays, suggesting non-specific activity. These results provide important information to prioritize chemicals for further investigation, and suggest possible modes of action of compounds in FXR signaling.
    [Show full text]
  • Pharmacology/Therapeutics II Block III Lectures 2013-14
    Pharmacology/Therapeutics II Block III Lectures 2013‐14 66. Hypothalamic/pituitary Hormones ‐ Rana 67. Estrogens and Progesterone I ‐ Rana 68. Estrogens and Progesterone II ‐ Rana 69. Androgens ‐ Rana 70. Thyroid/Anti‐Thyroid Drugs – Patel 71. Calcium Metabolism – Patel 72. Adrenocorticosterioids and Antagonists – Clipstone 73. Diabetes Drugs I – Clipstone 74. Diabetes Drugs II ‐ Clipstone Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones Date: Thursday, March 20, 2014-8:30 AM Reading Assignment: Katzung, Chapter 37 Key Concepts and Learning Objectives To review the physiology of neuroendocrine regulation To discuss the use neuroendocrine agents for the treatment of representative neuroendocrine disorders: growth hormone deficiency/excess, infertility, hyperprolactinemia Drugs discussed Growth Hormone Deficiency: . Recombinant hGH . Synthetic GHRH, Recombinant IGF-1 Growth Hormone Excess: . Somatostatin analogue . GH receptor antagonist . Dopamine receptor agonist Infertility and other endocrine related disorders: . Human menopausal and recombinant gonadotropins . GnRH agonists as activators . GnRH agonists as inhibitors . GnRH receptor antagonists Hyperprolactinemia: . Dopamine receptor agonists 1 Pharmacology & Therapeutics Neuroendocrine Pharmacology: Hypothalamic and Pituitary Hormones, March 20, 2014 Lecture Ajay Rana, Ph.D. 1. Overview of Neuroendocrine Systems The neuroendocrine
    [Show full text]
  • Use of Postmenopausal Hormone Therapy and Risk of Alzheimer’S BMJ: First Published As 10.1136/Bmj.L665 on 6 March 2019
    RESEARCH Use of postmenopausal hormone therapy and risk of Alzheimer’s BMJ: first published as 10.1136/bmj.l665 on 6 March 2019. Downloaded from disease in Finland: nationwide case-control study Hanna Savolainen-Peltonen,1,2 Päivi Rahkola-Soisalo,1 Fabian Hoti,3 Pia Vattulainen,3 Mika Gissler,4,5,6 Olavi Ylikorkala,1 Tomi S Mikkola1,2 1University of Helsinki and ABSTRACT ratio 1.09, 95% confidence interval 1.05 to 1.14) and Helsinki University Hospital, OBJECTIVES those of oestrogen-progestogen (1.17, 1.13 to 1.21). Obstetrics and Gynecology, To compare the use of hormone therapy between The risk increases in users of oestrogen-progestogen Haartmaninkatu 2, PO Box 140, FIN-00029 HUS, 00029 Finnish postmenopausal women with and without a therapy were not related to different progestogens Helsinki, Finland diagnosis for Alzheimer’s disease. (noreth isterone acetate, medroxyprogesterone 2 Folkhälsan Research Center, DESIGN acetate, or other progestogens); but in women Biomedicum, Helsinki, Finland younger than 60 at hormone therapy initiation, 3 Nationwide case-control study. EPID Research Oy, Espoo, these risk increases were associated with hormone Finland SETTING therapy exposure over 10 years. Furthermore, the 4National Institute for Health Finnish national population and drug register, age at initiation of systemic hormone therapy was and Welfare, Helsinki, Finland between 1999 and 2013. 5Karolinska Institute, not a decisive determinant for the increase in risk Department of Neurobiology, PARTICIPANTS of Alzheimer’s disease. The exclusive use of vaginal Care Sciences and Society, All postmenopausal women (n=84 739) in Finland estradiol did not affect the risk of the disease (0.99, Division of Family Medicine, who, between 1999 and 2013, received a diagnosis of 0.96 to 1.01).
    [Show full text]
  • Guidance on Bioequivalence Studies for Reproductive Health Medicines
    Medicines Guidance Document 23 October 2019 Guidance on Bioequivalence Studies for Reproductive Health Medicines CONTENTS 1. Introduction........................................................................................................................................................... 2 2. Which products require a bioequivalence study? ................................................................................................ 3 3. Design and conduct of bioequivalence studies .................................................................................................... 4 3.1 Basic principles in the demonstration of bioequivalence ............................................................................... 4 3.2 Good clinical practice ..................................................................................................................................... 4 3.3 Contract research organizations .................................................................................................................... 5 3.4 Study design .................................................................................................................................................. 5 3.5 Comparator product ....................................................................................................................................... 6 3.6 Generic product .............................................................................................................................................. 6 3.7 Study subjects
    [Show full text]